Key Points. Dual nanobody VHHs (dVHHs) targeting BCMA, achieved a high ORR in the treatment of relapsed or refractory plasma cell myeloma patients.Its effi
Key PointsIn our cohort of patients on modern systemic therapies, 6 validated VTE risk models showed poor to modest performance.Validating risk models in m
Care for patients with chronic lymphocytic leukemia has been revolutionized in the last decade as Bruton tyrosine kinase inhibitors and the B-cell lymphoma
Key PointsZebrafish demonstrate a unique balance of natural anticoagulants that mitigates severe FVIII deficiency.Zebrafish FVIII appears to circulate inde
Abstract. We report on 8 patients with ankyrin repeat domain 26 (ANKRD26)–related thrombocytopenia 2 (ANKRD26-RT) with elevated bone marrow myeloblasts and
Key Points. Sequential treatment with commercially available BCMA-directed CAR-T therapy in refractory myeloma is safe and efficaciousDuration of response
In this issue of Blood, Sidana et al report the largest real-world analysis of chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma (MM), c
The American Society of Hematology (ASH) is in search of Associate Editors to join ASH Clinical News, the Society’s monthly news magazine for the broader…
